NewLink Genetics (NLNK) Strengthens Patent on Cancer Therapy D-1MT

April 24, 2012 8:28 AM EDT Send to a Friend
NewLink Genetics (Nasdaq: NLNK) received a 'notice of allowance' from USPTO regarding its patent on cancer therapy D-1MT, allowing it broader rights to protection.

"These patents will strengthen our D-1MT franchise in the United States," commented Dr. Charles Link, NewLink's Chairman and CEO, "and should facilitate our ongoing discussions with potential development and marketing partners for this product candidate."

IDO pathway inhibitors, including D-1MT, represent a potential breakthrough approach to cancer therapy using small-molecule, anti-toleragenic product candidates intended to counteract a key mechanism by which tumors evade immune-mediated destruction.

Get Alerted Instantly When News Breaks on NLNK and Other Stocks with EasyStockAlerts.com


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News

Add Your Comment